Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment

Merck shared updates on the company’s oncology pipeline and focused R&D approach

BlueRock Therapeutics receives FDA RMAT designation for Parkinson’s disease cell therapy candidate bemdaneprocel

Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease

Merck inks MoU with KAIST to advance scientific collaboration

Partnership to facilitate collaborative research in academia and industry to further progress in life sciences

Valent BioSciences opens new addition at Melnik and Shafer Biorational Research Center

Greg was also central to the planning, design, and construction of this facility

Merck to acquire EyeBio for US$ 1.3 billion upfront payment

Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration

Roche and Hitachi High-Tech extend partnership for further breakthroughs in diagnostic testing

The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients

Indica Labs receives FDA clearance for HALO AP Dx digital pathology platform

For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner

Glenmark and BeiGene ink agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India

Dupixent late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD

Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19

SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients